Condition reference
VaccinationNon-core vaccine decision-making
Explore the linked guideline and related drug references. A matching drug entry does not establish a treatment recommendation.
WSAVA guideline
2024 Guidelines for the Vaccination of Dogs and Cats (2024)
Non-core vaccines are "highly recommended" only for animals whose geographical location and/or lifestyle (indoor-outdoor access, multi-pet households) places them at risk of infections not designated core (VGG 2024, Introduction). Selection is an individual risk-benefit decision, not a routine protocol. Most non-core products have short DOI and require annual boosters, unlike the triennial core MLV schedule. A separate "not recommended" category (CCoV, Giardia, M. canis, FIP vaccine) marks insufficient evidence of benefit.
2024 Guidelines for the Vaccination of Dogs and Cats, VGG/WSAVA, JSAP 2024, doi 10.1111/jsap.13718
Key findings
- Definitions: non-core = highly recommended only for at-risk animals (geography/lifestyle); "not recommended" = insufficient evidence anywhere (VGG 2024, Introduction).
- Leptospira is the boundary case: core where endemic + serogroups known + suitable vaccines exist; 2 doses 2–4 weeks apart then annual; restart 2 doses if ≥18 months lapsed (VGG 2024, Introduction; FAQs).
- Bordetella mucosal: single dose, annual, 13-month DOI; must never be injected parenterally; parenteral products need 2 doses 2–4 weeks apart (VGG 2024, Table 1).
- Borrelia (Lyme) and CIV: high-risk dogs only — Borrelia annually just before tick season (tick control is the mainstay; ACVIM consensus no agreement on routine use); CIV USA-licensed only, co-housed dogs, reduces severity not infection (VGG 2024, Table 1).
- Leishmania (A2, LiESP, recombinant Q): all annual, supplementary to ectoparasite control; vaccinated dogs can still transmit L. infantum; CHV-1 subunit is special-use for pregnant bitches (2-dose protocol in table) (VGG 2024, Table 1).
- Cats: FeLV non-core outside prevalent areas (risk-based); FIV (Japan/AU/NZ only) confounds antibody diagnostics, field efficacy 56%; C. felis and IN Bordetella only for sustained-risk/multi-cat settings (VGG 2024, Table 2).
Drugs named in WSAVA’s own guideline text
As printed in WSAVA’s document, not this app’s own extracted data — see “Related drugs in this reference” below for that.
(Dog)
Lapse ≥18 mo → restart
(Dog)
Pair with Bordetella mucosally
(Dog)
Never inject parenterally
(Dog)
Not IN/orally
(Dog)
Tick control mainstay
(Dog)
USA only; co-housed
(Dog)
Does not block transmission
(Dog (pregnant bitches))
Protects newborns
(Cat)
Test FeLV-negative first
(Cat)
Confounds serology
(Cat)
Multi-cat, confirmed disease
(Cat)
Large colonies
Recommendations
Select non-core vaccines only after assessing lifestyle, geography, local prevalence
Non-core (guiding principle)
Leptospira for all dogs in endemic regions with known serogroups
Core (regional) / Non-core elsewhere
Bordetella ± CPiV mucosal vaccine for dogs at CIRDC risk
Non-core for at-risk
Borrelia (tick control), CIV (US co-housed), Leishmania and CHV-1 (pregnant bitches) only per documented risk
Non-core (restricted)
FeLV risk-based outside core-rule areas; FIV/C. felis for sustained-risk cats
Non-core
Do not use CCoV, Giardia, M. canis or FIP vaccines
Not recommended
Annual boosters for most non-core products
Non-core interval rule
Related drugs in this reference (0)
No indication text currently matches this condition by name. Try a broader condition or search the drug reference directly. Absence of a match does not establish that treatment is unavailable.
From VGG 2024 (JSAP 2024, doi 10.1111/jsap.13718): Introduction, Tables 1–2, FAQs; schedules as printed; C. felis start-age discrepancy (8–9 vs 9 weeks) carried as [verify]. Core logic in T09/T10; shelter use in T41.